Bogle Investment Management’s Pacira BioSciences PCRX Stock Holding History

Bogle Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-159,166	Closed	-$6.06M	–	320
2019 Q1	$6.06M	Buy	159,166 +124,626	+361%	+$4.86M	0.46%	83
2018 Q4	$1.49M	Buy	+34,540	New	+$1.61M	0.12%	181
2017 Q1	–	Sell	-39,133	Closed	-$1.26M	–	360
2016 Q4	$1.26M	Buy	+39,133	New	+$1.31M	0.09%	228

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bogle Investment Management's PCRX Position: Q2 2019 in Review

Bogle Investment Management sold out of Pacira BioSciences (PCRX) in Q2 2019, closing a stake of 159,166 shares — an estimated $6.06M sold.

Bogle Investment Management first reported a position in PCRX in Q4 2016 and held it in 3 quarters. The position peaked at $6.06M in Q1 2019. 218 funds tracked by Wall St. Rank hold PCRX as of Q2 2019.

Bogle Investment Management reported no remaining Pacira BioSciences position as of Q2 2019 after selling out during the quarter.
Bogle Investment Management sold 159,166 Pacira BioSciences shares in Q2 2019, an estimated $6.06M.
Bogle Investment Management first reported a position in Pacira BioSciences in Q4 2016 and held it in 3 quarters.
Bogle Investment Management's Pacira BioSciences position peaked at $6.06M in Q1 2019.
218 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2019.

Based on Bogle Investment Management's 13F filing for Q2 2019, filed 13 Aug 2019.